Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ) signed a technology development cooperation agreement for the BIOS-0629 project.

Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ) announced that the company has recently reached a cooperation intention with Zhejiang Zhongshen Innovative Pharmaceutical Technology Co., Ltd. (referred to as "Zhongshen Innovative") on the independently developed BIOS-0629 project, and signed a "Technology Development Cooperation Agreement". Cooperation method: The company is responsible for the research and development, clinical trials, and registration declaration of the cooperative products. Zhongshen Innovation is responsible for the research and development transformation, production and sales after listing, and market expansion in the Greater China region. Transaction price: RMB 300 million. Settlement method: After the contract is signed, Zhongshen Innovation will pay RMB 300 million in milestone payments based on the research and development milestones. After the cooperative product is listed in the Greater China region, the company will also receive a 10% commission on sales revenue.